RUCHITA KARMAKAR, AMITY UNIVERSITY KOLKATA
Detection of Fucose is the cancer-marker in urine that helps in the initial screening of cancer. The Amperometric biosensing methods have the advantage of being fast, easy, and accurate results in urinalysis. Yet, the coexisting electroactive interferences as those of Ascorbic acid(AA), dopamine(DA), and uric acid(UA) make it difficult to have the exact results.
In this case, they used an Amperometric L-fucose biosensor as it remains undisturbed by such coexisting electroactive interferences. The biosensor works by utilizing direct electron transfer type bioelectrocatalysis of the pyrroloquinoline quinone(PQQ)-dependent pyranose dehydrogenase from Coprinopsis cinerea(CcPDH). The remote PQQ domain from CcPDH was in the immobilized condition on the gold nanoparticle (AuNP)-modified electrodes and, this acquired a less catalytic current at less potential following the oxidative potential of the interfering compounds.
By applying an operating potential of about -0.1V vs. Ag|AgCl(3M NaCl) authorized the detection of L-fucose by fully removing oxidation of AA, DA, and UA on the respective electrodes. By increasing the AuNP it helped to increase the area of the electrodes. It resulted in advancement in sensor performance. Thus the biosensor now could be actively used to quantify the concentration of L-fucose at any physiological levels which do not require urine processings, building it applicable to the practical use for testing urine.
Also read: ADOPTION OF GLUTEN-FREE DIET
One thought on “AMPEROMETRIC BIOSENSOR OF L-FUCOSE- FIRST SCREENING TEST OF CANCER?”